The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Shigeo ShimoseHideki IwamotoTomotake ShironoMasatoshi TanakaTakashi NiizekiMasahiko KajiwaraSatoshi ItanoYoichi YanoSatoru MatsugakiEtsuko MoriyamaYu NodaMasahito NakanoRyoko KuromatsuHironori KogaTakumi Kawaguchi

Published in: Cancer medicine (2023)

NLR <3 and m-ALBI grade 1 or 2a were predictive factors for conversion therapy, leading to cancer- and drug-free states in patients with u-HCC undergoing Atez/Bev therapy. Moreover, surgery or RFA may be suitable for conversion therapy for cancer-free status.

Keyphrases

papillary thyroid
squamous cell
minimally invasive
stem cells
emergency department
squamous cell carcinoma
childhood cancer
young adults
cell therapy
acute coronary syndrome
percutaneous coronary intervention
atrial fibrillation
smoking cessation